Correlation Between Creatine Phosphokinase and Pelvic Floor Muscle Strength in Postnatal Women

The purpose of this study is to determine the correlation between creatine phosphokinase and pelvic floor muscle strength in post-partum women.

Study Overview

• Status: Recruiting
• Conditions: Pelvic Floor; Rupture, Old (Postpartum)
• Intervention / Treatment: Other: Assessment of creatine phosphokinase; Other: Assessment of pelvic floor muscle strength

Detailed Description

Pelvic floor disorders (PFDs) are complex conditions affecting women's quality of life, including issues like pelvic organ prolapse, urinary incontinence, and pelvic pain. These disorders are prevalent, with 2.6-28.7% of women experiencing urinary incontinence and 20-50% suffering from pelvic organ prolapse. Accurate diagnosis requires a comprehensive understanding of pelvic musculoskeletal components and the interaction of multiple body systems.

Creatine phosphokinase (CPK) activity can be elevated in various conditions, including muscle diseases, burns, and after strenuous exercise. During childbirth, increased serum CPK levels have been observed, attributed to enzyme release from the uterus and placenta. CPK levels typically return to normal within six weeks postpartum.

To date, no study has explored the correlation between CPK levels and pelvic floor muscle strength in postnatal women. This research aims to fill this knowledge gap, potentially benefiting medical services and expanding understanding in women's health physical therapy.

• Study Type: Observational
• Enrollment (Estimated): 84

Contacts and Locations

• Study Contact: Name: Hadeer Mostafa, B.Sc; Phone Number: 01140561470; Email: doddapt@gmail.com
• Study Contact Backup: Name: Manal El-Shafei, PhD; Phone Number: manal.pt89@cu.edu.eg

Study Locations

• Egypt
  • Giza, Egypt
    • Recruiting
    • Hadeer Mostafa
    • Contact: Manal El-Shafei, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

They will be selected from the outpatient clinic of obstetrics and gynecology, Mataria Teaching Hospital, Cairo, Egypt.

Description

Inclusion Criteria:

• Post-partum women who delivered vaginally.
• Their ages will range from 25 to 35 years old.
• Their body mass index (BMI) will be <30 Kg/m2.
• CPK will be measured within the first six weeks (2nd-5th weeks) after delivery for all women.

Exclusion Criteria:

• Any dysfunction or associated injury or any pathological conditions which may affect the result of the study as cardiac abnormalities, thyroid dysfunction recurrent urinary tract infections, uncontrolled hypertension or diabetes mellitus.
• History of pelvic inflammatory disease, myoma and tumors, pelvic infection, ovarian cyst, any gynecological disease, any hormonal abnormality and any psychological problem.
• Pelvic floor dysfunction: genital prolapse, incontinence.
• Previous surgical operations as hysterectomy.
• Inability to understand the written and verbal instructions.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of creatine phosphokinase	It will be assessed through collecting a blood sample. The collected blood will be transferred into a sterile vacutainer tubes (9 mL) with anticoagulant and will be placed symmetrically into the centrifuge device. The serum will be separated from blood and will be put in epindoorf tubes and send immediately for analysis. Serum CPK will be quantitatively measured in units/liter (u/l) on a Vitros 950 automated analyzer shortly after the receipt of the specimen.	It will be measured within the first six weeks after delivery (2nd-5th weeks).
Assessment of pelvic floor muscle strength	It will be assessed by a biofeedback. Women will be positioned comfortably for pelvic floor muscle (PFM) strength assessment using a TG Myo feedback 420v vaginal electrode. The electrode, properly prepared and inserted, will measure vaginal closure pressure and deep PFM strength. The therapist will explain the display and will establish a one-minute baseline, noting any inconsistencies. Women will perform three 10-second maximum contractions, with the mean of these readings to be recorded. Muscle strength will be measured by peak maximum pressure and ability to sustain contraction.	It will be measured within the first six weeks after delivery (2nd-5th weeks).
Assessment of pelvic floor muscle endurance	It will be assessed by a biofeedback. Women will be positioned comfortably for pelvic floor muscle endurance assessment using a TG Myo feedback 420v vaginal electrode. The electrode will be properly prepared and inserted. The therapist will explain the display and will establish a one-minute baseline, noting any inconsistencies. Women will perform three 10-second maximum contractions. Muscle endurance will be measured as the time a sub-maximum contraction can be maintained before significant power reduction occurs.	It will be measured within the first six weeks after delivery (2nd-5th weeks).

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Study Chair: Hala Hanafy, PhD, Cairo University

Study record dates

Study Major Dates

• Study Start (Actual): July 20, 2024
• Primary Completion (Estimated): September 20, 2024
• Study Completion (Estimated): September 20, 2024

Study Registration Dates

• First Submitted: July 9, 2024
• First Submitted That Met QC Criteria: July 9, 2024
• First Posted (Actual): July 16, 2024

Study Record Updates

• Last Update Posted (Actual): August 1, 2024
• Last Update Submitted That Met QC Criteria: July 31, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: Creatine phosphokinase; Postnatal women; Pelvic floor strength
• Additional Relevant MeSH Terms: Wounds and Injuries; Rupture
• Other Study ID Numbers: P.T.REC/012/004954

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No